1. Home
  2. JYNT vs MOLN Comparison

JYNT vs MOLN Comparison

Compare JYNT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

SELL

Current Price

$6.21

Market Cap

100.7M

Sector

Miscellaneous

ML Signal

SELL

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$2.53

Market Cap

103.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JYNT
MOLN
Founded
2010
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Multi-Sector Companies
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
100.7M
103.5M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
JYNT
MOLN
Price
$6.21
$2.53
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$9.00
★ $9.97
AVG Volume (30 Days)
★ 63.8K
1.7K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.13
N/A
Revenue
★ $117,696,356.00
N/A
Revenue This Year
$5.87
N/A
Revenue Next Year
$0.18
N/A
P/E Ratio
$49.62
★ N/A
Revenue Growth
★ 15.49
N/A
52 Week Low
$6.42
$2.63
52 Week High
$10.67
$5.36

Technical Indicators

Market Signals
Indicator
JYNT
MOLN
Relative Strength Index (RSI) 32.77 26.89
Support Level N/A N/A
Resistance Level $9.49 $4.21
Average True Range (ATR) 0.27 0.12
MACD -0.05 -0.06
Stochastic Oscillator 2.49 0.41

Price Performance

Historical Comparison
JYNT
MOLN

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: